Glaukos (GKOS) Q2 2026 earnings review
Transformational Product Launches Drive 50% Sales Acceleration
Glaukos delivered a massive quarter, with Q2 revenue surging 50% YoY to a record $185.6M, crushing previous estimates. The growth was spearheaded by the explosive adoption of iDose TR ($74M) and the much-anticipated launch of Epioxa ($11M). While the company remains unprofitable with a GAAP net loss of $18.4M, the aggressive top-line expansion and favorable product mix pushed Non-GAAP gross margins to 85%. Management capitalized on this momentum by aggressively raising FY26 sales guidance from $620-635M to $680-700M.
🐂 Bull Case
Generating $74M in Q2, iDose TR adoption is accelerating rapidly. It is successfully shifting the treatment paradigm toward interventional glaucoma, validating management's long-term 'forever patient' strategy.
Management previously warned of a 'material dip' in Q2 Corneal Health revenue due to a Photrexa transition lag. Instead, the segment surged 48% YoY, generating $30.4M, indicating intense early demand for the incision-free Epioxa.
🐻 Bear Case
Despite 50% revenue growth, SG&A and R&D expenses jumped nearly 40%. The company is spending heavily to fuel these launches, meaning absolute cash flow breakeven remains a future target rather than a current reality.
International Glaucoma growth decelerated relative to the U.S. segment. Management explicitly cited global combo-cataract MIGS competition as a headwind factored into their guidance.
⚖️ Verdict: 🟢
Bullish. The sheer velocity of the iDose TR and Epioxa revenue ramps is undeniably impressive. While operating expenses remain high, the massive top-line beat, expanding gross margins, and dramatically raised guidance point to a highly successful commercial execution phase.
Key Themes
iDose TR Adoption is Accelerating
iDose TR sales jumped to ~$74M in Q2, up from $54M in 26Q1 and $31M a year ago. This sequential and year-over-year acceleration proves that surgeons are eagerly adopting this interventional glaucoma therapy. With CMS proposed rules potentially compressing physician fees for combination cataract-MIGS procedures, standalone Category III treatments like iDose TR are becoming increasingly attractive to comprehensive ophthalmologists.
Epioxa Launch Reverses 'Dip' Narrative
In previous quarters, management guided for a 'material dip' in Q2 2026 Corneal Health sales due to patient warehousing during the transition from Photrexa to Epioxa. Reversing expectations, the Corneal Health segment surged 48% YoY to $30.4M, with Epioxa contributing ~$11M early in its launch. With Epioxa's permanent J-code (J2789) going live on July 1, reimbursement friction should evaporate, paving the way for explosive second-half growth.
Product Mix Drives Margin Expansion
Stable and impressive margin accretion continues. Non-GAAP gross margin reached 85% in Q2, up 200 bps from 83% in 25Q2. This expansion is a direct mathematical result of the sales mix shifting heavily toward high-margin proprietary platforms like iDose TR and Epioxa.
Surging Operating Expenses Contradict Leverage Narrative
While management previously touted a 'clean line of sight' to cash-flow breakeven, expenses are accelerating. GAAP SG&A rose 39% YoY to $116.1M, and R&D jumped 40% YoY to $51.3M. While justifiable given the dual commercial launches, this significant step-up in spend ensures operating losses will persist in the near term despite 50% top-line growth.
International Glaucoma Decelerating Amid Competition
International Glaucoma posted $36.6M in sales. While this represents a respectable 17% YoY reported growth, it is a stable to decelerating metric compared to the explosive 64% growth seen in U.S. Glaucoma. Management explicitly highlighted 'combo-cataract MIGS competition globally' and competitive product trialing as ongoing headwinds.
Macroeconomic and Tariff Risks Lingering
Management continues to flag the 'global macroeconomic and geopolitical environment and associated uncertainties' as a factor in their guidance. While they noted minimal direct exposure to recent tariff policies because their manufacturing and sourcing are primarily U.S.-based, they remain cautious about secondary global supply chain effects.
Other KPIs
Accelerating dramatically. Growth hit 64% YoY, an intense step up from the ~58% YoY growth seen in 26Q1 and 45% YoY in 25Q2. This segment now accounts for 64% of the company's total revenue, cementing the U.S. Interventional Glaucoma transition as Glaukos's absolute core driver.
Stable. Up slightly from $280.5M sequentially. The company continues to carry zero traditional debt. This healthy cash cushion allows Glaukos to fully fund the aggressive SG&A marketing pushes for Epioxa and iDose TR without immediate dilution risk.
Guidance
Accelerating significantly. Management raised the midpoint by $62.5M (from $627.5M to $690M). At the $690M midpoint, this implies a massive 36% YoY growth rate compared to FY25's $507.4M. This upgrade clearly telegraphs management's confidence that the Q2 beat was not a one-off pull-forward, but structural momentum.
Key Questions
Epioxa J-Code Impact
With Epioxa generating roughly $11M under a slower miscellaneous J-code in Q2, how much warehoused demand is expected to unlock immediately in Q3 now that the permanent J2789 code is active?
Pacing the Path to Profitability
R&D and SG&A expenses grew ~40% YoY this quarter. As the heavy lifting for the Epioxa launch subsides, at what specific revenue run-rate do you expect to see meaningful absolute dollar reductions in non-GAAP operating losses?
International Strategy Pivot
You noted global combo-cataract MIGS competition as a headwind. Are there plans to alter pricing or commercial strategies internationally to defend market share, or is the focus purely on accelerating iStent infinite adoption in the EU?